特朗普再挥关税大棒，港股通创新药遭错杀？520880跌2.5%溢价飙升

Group 1 - The Hong Kong pharmaceutical market experienced a significant decline, with the Hong Kong Stock Connect Innovative Drug ETF (520880) opening down over 2.5% on September 26, 2023, as 35 out of 37 constituent stocks fell, including major players like BeiGene and Innovent Biologics, which dropped over 3% [1][2] - The recent announcement by U.S. President Trump regarding a new round of high tariffs on various imported products, including a 100% tariff on pharmaceutical products, has negatively impacted pharmaceutical stocks in Japan, South Korea, and Australia [3] - Analysts suggest that the impact of the U.S. tariffs on Chinese innovative drug companies is relatively limited, as these companies primarily rely on domestic demand and do not directly export to the U.S. market [4] Group 2 - The Hong Kong Stock Connect Innovative Drug ETF (520880) has seen a surge in net subscriptions, with over 6.4 billion CNY in net inflows across 16 out of the last 20 trading days, indicating strong investor interest despite market volatility [5][6] - The ETF focuses exclusively on innovative drug research and development companies, excluding contract research organizations (CROs), which positions it as a pure play on the innovative drug sector [6][7] - The index tracked by the ETF has shown a year-to-date increase of 119.75% before the recent adjustments, outperforming other innovative drug indices, and is expected to demonstrate stronger performance as the innovative drug market evolves [7][8]